Lv3
280 积分 2026-05-05 加入
OP0074 Preliminary results of CD19/BCMA Dual-Targeting FasTCAR-T Cells GC012F (AZD0120) in patients with refractory Systemic Lupus Erythematosus-an open-label, single-arm study
3天前
已完结
Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with moderately to severely active systemic lupus erythematosus: a phase I dose-escalation study
3天前
已完结
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
3天前
已完结
OP0141 LONG TERM SAFETY AND EFFICACY OF CAR-T CELL TREATMENT IN REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS - DATA FROM THE FIRST SEVEN PATIENTS
3天前
待确认
OP0202 RESET-SLE: CLINICAL TRIAL EVALUATING RESE-CEL (RESECABTAGENE AUTOLEUCEL), A FULLY HUMAN, AUTOLOGOUS 4-1BB ANTI-CD19 CAR T CELL THERAPY IN NON-RENAL SLE AND LUPUS NEPHRITIS
3天前
求助中
Safety of CD19-directed CAR T-cell therapy in refractory systemic lupus erythematosus versus B-cell lymphoma - A single-center experience
3天前
已完结
OP0279 CAR-T CELL TREATMENT OF REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS- SAFETY AND PRELIMINARY EFFICACY DATA FROM THE FIRST FOUR PATIENTS
3天前
已完结
OP0032 Treatment of Refractory Systemic Lupus Erythematosus with Off-the-Shelf iPSC-derived Anti-CD19 CAR T-cell Therapy
3天前
求助中
FIRST TWO US PATIENTS WITH LUPUS NEPHRITIS (LN) TREATED WITH ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY: PRELIMINARY RESULTS FROM THE KYSA-1 PHASE 1, MULTICENTER STUDY OF KYV-101
3天前
已完结
皖公网安备34019202002308
